Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Stu-Reference-Cited by-同舟云学术

Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Stu

Published:2012-06-26 Issue:1 Volume:132 Page:236-245
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Stintzing Sebastian,Kapaun Christine,Laubender Rüdiger Paul,Jung Andreas,Neumann Jens,Modest Dominik Paul,Giessen Clemens,Moosmann Nicolas,Wollenberg Andreas,Kirchner Thomas,Heinemann Volker

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference41 articles.

1. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer;Van Cutsem;N Engl J Med,2009

2. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer;Bokemeyer;J Clin Oncol,2009

3. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab;De Roock;J Am Med Assoc,2010

4. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab;Khambata-Ford;J Clin Oncol,2007

5. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer;Loupakis;Br J Cancer,2009

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Preliminary Study Examining the Correlation between EGFRI Treatment, Clinic Dermatoscopy Features, and Serum Levels of Anti-Alpha-Galactosyl IgE in Colorectal Cancer Patients;Gastroenterology Insights;2024-06-17

2. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-06

3. Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM;ESMO Open;2024-04

4. Gastrointestinal Malignancy: Genetic Implications to Clinical Applications;Cancer Treatment and Research;2024

5. Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study;Cancer Chemotherapy and Pharmacology;2023-11-28